Page 2 of 7 SEC Filing
13D
CUSIP No. 91911K102 Page 2
1 Name of
reporting person
Pershing Square Capital Management, L.P.
2 Check the appropriate box if a member
of a group
(a) ¨ (b) ¨
3 SEC use only
4 Source of funds
OO (See Item 3)
5 Check box if disclosure of legal
proceedings is required pursuant to Items 2(d) or 2(e)
¨
6 Citizenship or place of
organization
Delaware
Number of
shares
beneficially
owned by
each
reporting
person
with
7 Sole voting power
0
8 Shared voting power
30,711,122
9 Sole dispositive power
0
10 Shared dispositive power
30,711,122
11 Aggregate amount beneficially owned by each reporting person
30,711,122
12 Check box if the aggregate amount in
Row (11) excludes certain shares
¨
13 Percent of class represented by amount
in Row (11)
9.0%(1)
14 Type of reporting person
IA
(1) Calculated based on 343,101,797 shares of common stock, no par value, of Valeant Pharmaceuticals International, Inc. outstanding as of October 19, 2015, as reported on Valeant Pharmaceuticals International, Inc.s
quarterly report filed on Form 10-Q on October 26, 2015.
Follow Bausch Health Companies Inc. (NYSE:BHC)
Follow Bausch Health Companies Inc. (NYSE:BHC)
Receive real-time insider trading and news alerts
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
13D
| CUSIP No. 91911K102 | Page 2 |
| 1 | Name of Pershing Square Capital Management, L.P. | |||||
| 2 | Check the appropriate box if a member (a) ¨ (b) ¨ | |||||
| 3 | SEC use only | |||||
| 4 | Source of funds OO (See Item 3) | |||||
| 5 | Check box if disclosure of legal ¨ | |||||
| 6 | Citizenship or place of Delaware | |||||
| Number of shares beneficially owned by each reporting person with | 7 | Sole voting power 0 | ||||
| 8 | Shared voting power 30,711,122 | |||||
| 9 | Sole dispositive power 0 | |||||
| 10 | Shared dispositive power 30,711,122 | |||||
| 11 | Aggregate amount beneficially owned by each reporting person 30,711,122 | |||||
| 12 | Check box if the aggregate amount in ¨ | |||||
| 13 | Percent of class represented by amount 9.0%(1) | |||||
| 14 | Type of reporting person IA | |||||
| (1) | Calculated based on 343,101,797 shares of common stock, no par value, of Valeant Pharmaceuticals International, Inc. outstanding as of October 19, 2015, as reported on Valeant Pharmaceuticals International, Inc.s quarterly report filed on Form 10-Q on October 26, 2015. |
Follow Bausch Health Companies Inc. (NYSE:BHC)
Follow Bausch Health Companies Inc. (NYSE:BHC)
Receive real-time insider trading and news alerts
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
